Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Juvenile 2Inflammation 2Asthma 2Wilms Tumor 1Vasculitis 1Uveitis 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Respiratory Distress Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lupus Nephritis 1Lung Injury 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Immunoglobulin Light-chain Amyloidosis 1Granulomatosis with Polyangiitis 1Fatigue Syndrome, Chronic 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Bronchiolitis Obliterans 1Blast Crisis 1

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × Etanercept × Clear all
NCT00224393 2023-05-30

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

The Cleveland Clinic

Phase 2 Completed
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡